Latest news with #AptarDigitalHealth
Yahoo
14-04-2025
- Health
- Yahoo
Aptar Digital Health Reports Positive Impact of iPUMP® on Sublingual Liquid Allergen Immunotherapy Adherence
CRYSTAL LAKE, Ill., April 14, 2025--(BUSINESS WIRE)--Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announces the positive results from the SPEED1 survey, showcasing the impact of the iPUMP® connected assistant on adherence to Stallergenes Greer's sublingual liquid immunotherapy (SLIT). The results will be presented by Stallergenes Greer, a global leader in allergy therapeutics and long-standing partner of Aptar Digital Health, at the upcoming CFA congress (Congrès Francophone d'Allergologie) in Paris, France from April 15 to 18, 2025. The SPEED survey showed a 15% increase in treatment adherence for patients using iPUMP®. Moreover, for children aged between 5 and 12 years, parental involvement in treatment administration dropped from 50% to 28% over three months, while the proportion of children independently taking their medication rose from 24% to 58%. Notably, 90% of parents felt reassured by the connected assistant, with half of them feeling completely at ease with treatment administration, compared to 36% of respondents in the non-iPUMP® group. iPUMP®, developed in conjunction with Stallergenes Greer, supports adherence to personalized SLIT treatments by helping to ensure patients adopt the correct dosing technique, duration and frequency of treatment. This innovative and easy-to-use tool is connected to a companion mobile application and provides direct access to the personalized treatment protocol prescribed to each patient by their physician. Launched in February 2023 in France, it has been used by over 9,000 patients to date. iPUMP® helps support patients in improving treatment adherence to optimize effectiveness while offering a history-tracking function for precise medication monitoring. By supporting Stallergenes Greer in their mission to empower individuals and improve treatment outcomes, Aptar Digital Health fosters its go-to partner position in the pharmaceutical industry for the development and operation of digital health and connected solutions. Elena Rizova, Chief Medical Officer at Stallergenes Greer, stated, "Findings of the SPEED survey underscore the role of connected health solutions in improving both treatment adherence and patient confidence, which are key elements in achieving successful therapeutic outcomes." She added, "Innovation is at the heart of what we do and iPUMP®, by catering to the needs expressed by patients and healthcare professionals, meets their expectations and provides a solution to enhance treatment management and overall allergy care." Marcus Bates, VP Business Development & Global Head of Respiratory at Aptar Digital Health, commented, "The strong results of the SPEED survey pave the way for wider adoption of digital and connected solutions for allergy management, enabling new patients to access a simple, easy-to-use solution that can help track adherence and stay engaged to achieve better health outcomes." The SPEED survey results establish a strong foundation for broader adoption of iPUMP®, supporting Stallergenes Greer's commitment to innovate for the benefit of patients, caregivers and the medical community. About Aptar Digital Health Aptar Pharma's Digital Health division is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health's offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit and About Stallergenes Greer Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit 1 The SPEED real-life study was conducted by AplusA for Stallergenes Greer between May 29 and November 29, 2024. This online questionnaire, aimed at measuring the impact perceived by patients after three months of treatment with allergen immunotherapy (AIT) using Aptar Digital Health's iPUMP® connected assistant, included 104 pediatric patients over 5 years of age and 77 adolescent and adult patients over 13 years of age. View source version on Contacts Media Contact: Ciara JacksonAptar Pharma+49 151 1951
Yahoo
03-04-2025
- Business
- Yahoo
SHL Medical opens new autoinjector manufacturing facility in US
Swiss-based SHL Medical has opened a new autoinjector manufacturing facility in North Charleston, South Carolina, US, with a $220m investment. This 360,000ft² site will help the company meet the increasing global demand for autoinjectors, particularly in the cardiometabolic sector. The facility will manufacture the autoinjectors used in medications in various therapeutic areas, including endocrine and metabolic disorders, musculoskeletal diseases, and dermatology. SHL Medical noted that the North Charleston site is poised to offer efficiency, precision, and quality drug delivery solutions, with its medical device injection moulding technology and fully automated assembly capabilities. The new facility has generated more than 300 local employment opportunities. It utilises the current final assembly, labelling, and packaging operations in Deerfield Beach, Florida, and benefits from the integration of recent acquisitions under the company's sub-group SHL Advantec, which offers automation and tooling solutions for the healthcare sector. SHL Medical stated that it is on track to deliver 1.5 billion devices to customers this year. SHL Medical chairman and CEO Ulrich Faessler said: 'US-based production is a major step forward in our global expansion and reinforces our position as the leader in providing end-to-end drug delivery solutions. 'With our established site in Taiwan and the upcoming facility in Switzerland, we will be the only autoinjector manufacturer operating across three continents, bringing us even closer to our customers.' With more than 5,000 employees across Switzerland, Sweden, Taiwan, and the US, SHL Medical claims to leverage its in-house manufacturing offerings to deliver end-to-end services. In June 2025, Aptar Digital Health partnered with SHL Medical to improve the patient experience in injectable therapies by integrating digital health solutions with drug delivery systems. "SHL Medical opens new autoinjector manufacturing facility in US" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
